Cardiovascular Effects of Diabetes: A Review of Management

Dr. Arshid Rafiq[1], Dr. Hilal Azad[2], Rutba Maqbool[3], Sumairah Mushtaq[4], Sumeena Altaf[5], Kaisar Bakshi[6]
[1,2,3,4,5,6] *AMRL ventures*

***Abstract*—Diabetes mellitus (DM) is a major global public health concern and a well-established independent risk factor for cardiovascular disease (CVD), the leading cause of morbidity and mortality among individuals with diabetes. Persistent hyperglycemia, insulin resistance, endothelial dysfunction, oxidative stress, chronic inflammation, and dyslipidemia collectively contribute to the initiation and progression of cardiovascular complications, including coronary artery disease, heart failure, stroke, peripheral arterial disease, and diabetic cardiomyopathy. These complex pathophysiological mechanisms accelerate atherosclerosis, impair vascular function, and promote adverse cardiac remodeling. This review provides a comprehensive overview of the molecular and cellular mechanisms linking diabetes to cardiovascular disease, with particular emphasis on the roles of chronic hyperglycemia, advanced glycation end products, oxidative stress, endothelial dysfunction, and insulin resistance in cardiovascular injury. In addition, the review summarizes current evidence-based strategies for cardiovascular risk reduction in patients with diabetes, including optimization of glycemic control, blood pressure management, lipid lowering therapy, antiplatelet treatment, and lifestyle modification. Pharmacological advances, particularly the use of sodium glucose cotransporter-2 (SGLT2) inhibitors and other cardioprotective agents, have further improved cardiovascular outcomes in this high-risk population. Early diagnosis, individualized treatment strategies, and comprehensive management of both glycemic status and associated cardiovascular risk factors are essential for reducing cardiovascular morbidity and mortality. A multidisciplinary approach that integrates pharmacological therapy with lifestyle interventions remains the cornerstone of preventing cardiovascular complications and improving long term clinical outcomes in individuals with diabetes.**

I. INTRODUCTION

Diabetes mellitus (DM) is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from impaired insulin secretion, insulin action, or both. It has emerged as one of the most significant global public health challenges, with its prevalence increasing steadily over recent decades owing to population aging, rapid urbanization, sedentary lifestyles, unhealthy dietary habits, and the rising prevalence of obesity. Beyond its metabolic consequences, diabetes is a major contributor to cardiovascular disease (CVD), which remains the leading cause of morbidity and mortality among individuals with diabetes. According to the International Diabetes Federation (IDF), approximately 537 million adults were living with diabetes worldwide in 2021. This number is projected to increase to 643 million by 2030 and 783 million by 2045, highlighting the growing global burden of the disease. The prevalence of diabetes is particularly high in low and middle income countries, where limited healthcare resources, delayed diagnosis, and inadequate access to treatment contribute to poor disease control and increased complications. The economic burden of diabetes is equally substantial because of escalating healthcare costs associated with long term treatment and the management of diabetes related complications. The epidemiology of diabetes varies considerably across different regions. In the United States, the Centers for Disease Control and Prevention (CDC) estimated that more than 34 million individuals, representing approximately 10.5% of the population, were living with diabetes in 2020. Similar trends have been observed in many developed nations, while developing countries continue to experience the fastest rise in disease prevalence. Regions such as the

Middle East and North Africa report some of the highest prevalence rates, primarily driven by rapid urbanization, dietary transitions, and reduced physical activity. Although Sub Saharan Africa currently has a comparatively lower prevalence, it is projected to experience one of the fastest increases in diabetes incidence, posing a significant challenge to already overburdened healthcare systems.

Cardiovascular disease is the most serious complication of diabetes and accounts for the majority of diabetes related deaths. Individuals with diabetes are at a substantially higher risk of developing coronary artery disease, heart failure, cerebrovascular disease, and peripheral arterial disease than those without diabetes. Chronic hyperglycemia promotes endothelial dysfunction, oxidative stress, chronic inflammation, and the formation of advanced glycation end products (AGEs), all of which accelerate the development of atherosclerosis and increase the risk of plaque instability, thrombosis, myocardial infarction, and ischemic stroke.

The cardiovascular risk associated with diabetes is further amplified by the frequent coexistence of hypertension, dyslipidemia, obesity, and insulin resistance. Diabetic dyslipidemia is typically characterized by elevated triglyceride levels, reduced high-density lipoprotein (HDL) cholesterol, and an increased proportion of small, dense low-density lipoprotein (LDL) particles, which possess greater atherogenic potential. These metabolic abnormalities contribute to accelerated vascular injury and the progression of atherosclerotic cardiovascular disease.

In addition to vascular complications, diabetes directly affects myocardial structure and function, leading to diabetic cardiomyopathy. This condition develops independently of coronary artery disease or hypertension and is characterized by myocardial fibrosis, ventricular hypertrophy, mitochondrial dysfunction, impaired myocardial metabolism, and progressive systolic and diastolic dysfunction. These pathological changes substantially increase the risk of heart failure among individuals with diabetes.

Numerous epidemiological studies have demonstrated that individuals with diabetes have a two- to four-fold greater risk of cardiovascular mortality than the general population. Consequently, effective diabetes management extends beyond glycemic control and requires comprehensive management of all modifiable cardiovascular risk factors. Early diagnosis, individualized pharmacological therapy, lifestyle modification, and aggressive cardiovascular risk reduction strategies are essential for preventing complications and improving long-term clinical outcomes. This review summarizes the current understanding of the pathophysiological mechanisms linking diabetes mellitus and cardiovascular disease, with particular emphasis on hyperglycemia, insulin resistance, endothelial dysfunction, oxidative stress, inflammation, and diabetic cardiomyopathy. Furthermore, it discusses contemporary evidence-based strategies for cardiovascular risk reduction, including glycemic optimization, blood pressure control, lipid management, antiplatelet therapy, and lifestyle interventions, highlighting their role in improving cardiovascular outcomes in patients with diabetes.

II. THE ROLE OF HYPERGLYCEMIA IN DIABETIC

1. Cardiomyopathy

Persistent hyperglycemia is the principal metabolic abnormality in diabetes mellitus and plays a central role in the development and progression of diabetic cardiomyopathy. Diabetic cardiomyopathy is characterized by structural and functional alterations of the myocardium that occur independently of coronary artery disease or hypertension and ultimately increase the risk of heart failure. Chronic hyperglycemia initiates a cascade of metabolic and molecular abnormalities, including the formation of advanced glycation end products (AGEs), oxidative stress, endothelial dysfunction, mitochondrial injury, inflammation, and impaired cellular metabolism, all of which contribute to progressive myocardial damage and adverse cardiac remodeling. [1]

2. Hyperglycemia and Cardiovascular Injury

Sustained elevation of blood glucose adversely affects both the myocardium and the vascular endothelium. Hyperglycemia promotes endothelial dysfunction by reducing nitric oxide (NO) bioavailability, increasing oxidative stress, and stimulating inflammatory signaling pathways. These changes impair vascular homeostasis, promote vasoconstriction, and accelerate atherosclerosis, thereby increasing the risk of coronary artery disease, myocardial infarction, and heart failure. [2]

3. Advanced Glycation End Products

Chronic hyperglycemia accelerates the non-enzymatic glycation of proteins, lipids, and nucleic acids, resulting in the formation of AGEs. These molecules accumulate within the myocardium and vascular tissues, where they increase collagen cross-linking, reduce myocardial elasticity, and promote interstitial fibrosis. Interaction of AGEs with their receptor (RAGE) activates multiple intracellular signaling pathways, leading to oxidative stress, chronic inflammation, endothelial dysfunction, and vascular remodeling. Collectively, these processes accelerate atherosclerosis and contribute to the progression of diabetic cardiomyopathy. [3]

4. Endothelial Dysfunction

The vascular endothelium plays a critical role in maintaining vascular tone and homeostasis. Hyperglycemia disrupts endothelial function by impairing nitric oxide synthesis and increasing the production of vasoconstrictors, particularly endothelin-1. Reduced no. bioavailability limits endothelium dependent vasodilation, whereas increased endothelin-1 promotes vasoconstriction and vascular stiffness. Consequently, coronary blood flow is compromised, myocardial perfusion decreases, and the risk of ischemic cardiovascular events increases. [4–7]

5. Oxidative Stress and Inflammation

Oxidative stress represents one of the key mechanisms linking hyperglycemia to cardiovascular injury. Excess intracellular glucose enhances the production of reactive oxygen species (ROS) through mitochondrial dysfunction and activation of several metabolic pathways. Excessive ROS damages cellular proteins, lipids, and DNA while simultaneously impairing endothelial function and myocardial contractility. [8]

In addition to direct cellular injury, ROS activate multiple inflammatory signaling pathways, including nuclear factor-kappa B (NF-κB), resulting in sustained production of pro-inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6). Persistent low-grade inflammation further promotes myocardial fibrosis, endothelial dysfunction, and progression of atherosclerosis, thereby increasing cardiovascular morbidity and mortality in individuals with diabetes. [9–12]

6. Pathophysiological Consequences

The combined effects of hyperglycemia induced AGE accumulation, endothelial dysfunction, oxidative stress, and chronic inflammation progressively impair myocardial structure and function. These mechanisms promote cardiomyocyte apoptosis, extracellular matrix remodeling, myocardial fibrosis, ventricular hypertrophy, and impaired mitochondrial energy production. As myocardial stiffness increases and ventricular relaxation becomes compromised, both diastolic and systolic dysfunction develop, eventually leading to diabetic cardiomyopathy and heart failure.

Understanding the molecular pathways through which hyperglycemia induces cardiovascular injury has important therapeutic implications. Early and sustained glycemic control, together with interventions targeting oxidative stress, inflammation, endothelial dysfunction, and metabolic abnormalities, may delay or prevent the progression of diabetic cardiomyopathy and improve long-term cardiovascular outcomes in patients with diabetes. [12]

III. PATHOPHYSIOLOGY

The pathophysiology of cardiovascular disease (CVD) in diabetes mellitus (DM) is multifactorial and involves a complex interplay of metabolic, inflammatory, and hemodynamic abnormalities. Persistent hyperglycemia, insulin resistance, dyslipidemia, oxidative stress, endothelial dysfunction, chronic inflammation, and a prothrombotic state collectively contribute to vascular injury, accelerated atherosclerosis, and myocardial dysfunction. These interconnected mechanisms ultimately lead to the development of diabetic cardiomyopathy, coronary artery disease, heart failure, cerebrovascular disease, and peripheral arterial disease. [13,14]

A. Insulin Resistance

Insulin resistance is a hallmark of type 2 diabetes mellitus and plays a pivotal role in the development of cardiovascular complications. Under normal physiological conditions, insulin promotes glucose uptake by skeletal muscle and adipose tissue while suppressing hepatic glucose production. In insulin resistant states, these actions are impaired, resulting in persistent hyperglycemia and compensatory hyperinsulinemia.

Beyond disturbances in glucose metabolism, insulin resistance adversely affects vascular function by reducing nitric oxide bioavailability, increasing oxidative stress, and activating pro-inflammatory signaling pathways. These alterations promote endothelial dysfunction, vascular stiffness, and accelerated atherosclerosis, thereby substantially increasing cardiovascular risk. [15]

B. Dyslipidemia

Diabetic dyslipidemia is another major contributor to cardiovascular disease. It is typically characterized by elevated triglyceride concentrations, reduced high density lipoprotein (HDL) cholesterol levels, and an increased proportion of small, dense low-density lipoprotein (LDL) particles. These highly atherogenic lipoproteins readily penetrate the vascular endothelium, undergo oxidation, and stimulate inflammatory responses that accelerate plaque formation and progression.

The coexistence of insulin resistance and dyslipidemia further amplifies oxidative stress and endothelial injury, creating a favorable environment for the development of atherosclerotic cardiovascular disease. [16]

C. Prothrombotic State

Diabetes is associated with a hypercoagulable or prothrombotic state that significantly increases the risk of thrombotic cardiovascular events. Hyperglycemia and insulin resistance promote platelet hyperreactivity, increase coagulation factor activity, and impair fibrinolysis. Elevated concentrations of plasminogen activator inhibitor-1 (PAI-1), fibrinogen, and inflammatory mediators further enhance thrombus formation.

This imbalance between coagulation and fibrinolysis increases the likelihood of acute cardiovascular events, including myocardial infarction, ischemic stroke, and peripheral arterial thrombosis. [17]

D. Diabetic Cardiomyopathy

Diabetic cardiomyopathy is a distinct clinical entity characterized by structural and functional abnormalities of the myocardium in the absence of coronary artery disease, hypertension, or valvular heart disease. Chronic metabolic disturbances in diabetes progressively impair myocardial architecture, contractility, and ventricular function, ultimately predisposing patients to heart failure. [18]

E. Myocardial Fibrosis and Hypertrophy

Persistent hyperglycemia stimulates the accumulation of extracellular matrix proteins, particularly collagen, within the myocardium. Excessive collagen deposition results in myocardial fibrosis, increased ventricular stiffness, and impaired diastolic relaxation. Simultaneously, cardiomyocyte hypertrophy develops as an adaptive response to chronic metabolic stress and increased myocardial workload. These structural changes progressively impair both systolic and diastolic cardiac function. [19]

F. Mitochondrial Dysfunction

Mitochondria are the primary source of energy production in cardiomyocytes. In diabetes, chronic hyperglycemia and excessive fatty acid oxidation disrupt mitochondrial function, reducing ATP generation while increasing the production of reactive oxygen species. This energy deficit compromises myocardial contractility and accelerates cardiomyocyte injury, apoptosis, and ventricular dysfunction. [20]

G. Advanced Glycation End Products and Metabolic Injury

Persistent hyperglycemia promotes the accumulation of advanced glycation end products (AGEs) within myocardial tissue. AGEs increase collagen cross-linking, impair myocardial compliance, and activate inflammatory and oxidative signaling pathways through receptor for advanced glycation end products (RAGE)-mediated mechanisms. In addition, altered lipid metabolism leads to excessive intracellular accumulation of free fatty acids and toxic lipid intermediates, further aggravating myocardial injury and metabolic dysfunction. [21]

H. Oxidative Stress and Chronic Inflammation

Oxidative stress and chronic low-grade inflammation are central mechanisms in the pathogenesis of diabetic cardiomyopathy. Excessive reactive oxygen species damage cellular proteins, lipids, mitochondrial DNA, and cellular membranes, leading to impaired cardiomyocyte survival and function. Simultaneously, activation of inflammatory pathways promotes the release of cytokines, including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6), which contribute to myocardial fibrosis, ventricular remodeling, and progressive cardiac dysfunction. [22]

I. Impaired Cardiac Contractility

The cumulative effects of fibrosis, hypertrophy, mitochondrial dysfunction, oxidative stress, inflammation, and metabolic derangements progressively impair myocardial contraction and relaxation. Initially, patients develop left ventricular diastolic dysfunction, which may progress to systolic dysfunction and ultimately heart failure. These pathological alterations account for the increased incidence of heart failure and cardiovascular mortality observed in individuals with diabetes. [23]

Overall, the pathophysiology of diabetic cardiovascular disease reflects the complex interaction between metabolic abnormalities and chronic vascular injury. A comprehensive understanding of these mechanisms provides the foundation for targeted therapeutic interventions aimed at preventing myocardial damage, slowing disease progression, and improving cardiovascular outcomes in patients with diabetes.

IV. MANAGEMENT

The management of diabetes mellitus aims not only to achieve optimal glycemic control but also to reduce the risk of cardiovascular disease (CVD) through comprehensive management of associated cardiovascular risk factors. Contemporary treatment strategies combine lifestyle modification with evidence-based pharmacological therapy to prevent vascular complications, delay disease progression, and improve long-term clinical outcomes. An individualized, patient-centered approach remains the cornerstone of effective diabetes care. [24]

A. Glycemic Control

Optimal glycemic control is fundamental to preventing both microvascular and macrovascular complications of diabetes. Persistent hyperglycemia contributes to endothelial dysfunction, oxidative stress, inflammation, and the formation of advanced glycation end products (AGEs), all of which accelerate cardiovascular injury. Therefore, maintaining individualized glycemic targets through lifestyle modification and pharmacological therapy is essential for reducing cardiovascular risk and improving overall prognosis. [25]

B. Lifestyle Modification

Lifestyle intervention is the foundation of diabetes management. A balanced diet rich in vegetables, fruits, whole grains, legumes, lean proteins, and unsaturated fats, while limiting refined carbohydrates, processed foods, saturated fats, and sugar sweetened beverages, improves glycemic control and cardiovascular health. Regular physical activity, including at least 150 minutes of moderate-intensity aerobic exercise per week combined with resistance training, enhances insulin sensitivity, facilitates weight reduction, lowers blood pressure, and improves lipid metabolism. Smoking cessation, adequate sleep, and stress reduction further contribute to cardiovascular risk reduction. [26]

C. Pharmacological Therapy

Pharmacological treatment should be individualized according to glycemic status, comorbidities, renal function, and cardiovascular risk.

Metformin remains the preferred first-line therapy for most patients with type 2 diabetes because of its efficacy, favorable safety profile, low risk of hypoglycemia, and potential cardiovascular benefits.

Sodium glucose cotransporter-2 (SGLT2) inhibitors have demonstrated significant cardiovascular and renal protective effects beyond glucose lowering. Large clinical trials have shown reductions in hospitalization for heart failure, progression of chronic kidney disease, and cardiovascular mortality in high-risk patients.

Glucagon-like peptide-1 (GLP-1) receptor agonists have also been shown to reduce major adverse cardiovascular events, promote weight loss, and improve glycemic control, making them valuable therapeutic options for patients with established atherosclerotic cardiovascular disease or multiple cardiovascular risk factors. [27]

D. Blood Pressure Management

Hypertension frequently coexists with diabetes and substantially increases the risk of cardiovascular complications. Effective blood pressure control reduces the incidence of myocardial infarction, stroke, heart failure, and diabetic nephropathy.

Lifestyle interventions including dietary sodium restriction, weight reduction, regular exercise, moderation of alcohol intake, and smoking cessation remain the initial components of blood pressure management. However, most patients require pharmacological therapy to achieve recommended blood pressure targets.

Angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are generally preferred because of their cardioprotective and Reno protective effects, particularly in patients with diabetic kidney disease. Calcium channel blockers, thiazide or thiazide like diuretics, and beta-blockers may be added according to individual clinical indications and treatment goals. [28–30]

E. Lipid Management

Dyslipidemia is a major contributor to accelerated atherosclerosis in diabetes. Comprehensive lipid management substantially reduces the risk of cardiovascular events.

Lifestyle modification remains the first line intervention and includes adherence to a heart healthy diet, regular physical activity, weight management, and smoking cessation. Nevertheless, pharmacological therapy is required for most adults with diabetes because of their elevated cardiovascular risk. Statins are the cornerstone of lipid-lowering therapy and have consistently demonstrated reductions in cardiovascular morbidity and mortality. For patients who fail to achieve recommended low density lipoprotein cholesterol (LDL-C) targets despite maximally tolerated statin therapy, additional agents such as ezetimibe, PCSK9 inhibitors, or bempedoic acid may be considered according to current clinical guidelines and individual cardiovascular risk profiles. [31–33]

F. Antiplatelet Therapy

Platelet dysfunction and a prothrombotic state increase the risk of thrombotic cardiovascular events in individuals with diabetes. Antiplatelet therapy plays an important role in secondary prevention among patients with established cardiovascular disease.

Low dose aspirin remains the most commonly prescribed antiplatelet agent for secondary prevention. In selected patients, particularly those with acute coronary syndrome or after percutaneous coronary intervention, dual antiplatelet therapy with aspirin and a P2Y12 receptor inhibitor (such as clopidogrel or ticagrelor) may be indicated for an appropriate duration based on bleeding and ischemic risk.

Routine aspirin use for primary prevention should be individualized after carefully balancing potential cardiovascular benefits against the increased risk of bleeding. [34–37]

G. Lifestyle Modification and Cardiovascular Risk Reduction

Lifestyle modification remains the cornerstone of comprehensive cardiovascular risk reduction in diabetes and should accompany all pharmacological interventions.

A heart healthy dietary pattern improves glycemic control, blood pressure, lipid levels, and body weight while reducing systemic inflammation. Regular aerobic and resistance exercise enhances insulin sensitivity, improves endothelial function, and lowers cardiovascular risk. Smoking cessation significantly decreases the incidence of myocardial infarction, stroke, and peripheral arterial disease. Maintaining a healthy body weight, particularly reducing central obesity, improves metabolic control and lowers cardiovascular risk. In addition, stress-management strategies including mindfulness, relaxation techniques, and cognitive behavioral approaches may improve treatment adherence, glycemic control, and overall quality of life. [38–43]

Overall, successful management of diabetes requires a multidisciplinary, individualized approach that integrates lifestyle modification, optimization of glycemic control, aggressive management of hypertension and dyslipidemia, and appropriate use of cardioprotective medications. Early implementation of evidence-based interventions is essential for reducing cardiovascular morbidity and mortality and improving long-term clinical outcomes.

V. CONCLUSION

Diabetes mellitus is a major global health challenge and a leading contributor to cardiovascular morbidity and mortality. The close relationship between diabetes and cardiovascular disease is mediated by multiple interconnected mechanisms, including chronic hyperglycemia, insulin resistance, endothelial dysfunction, oxidative stress, inflammation, dyslipidemia, and the formation of advanced glycation end products. These pathophysiological processes accelerate atherosclerosis, impair myocardial function, and promote the development of diabetic cardiomyopathy, coronary artery disease, heart failure, stroke, and peripheral arterial disease.

Early identification and comprehensive management of cardiovascular risk factors are essential to reducing the burden of cardiovascular complications in individuals with diabetes. Effective treatment extends beyond glycemic control and requires a multifaceted approach incorporating blood pressure optimization, lipid management, antiplatelet therapy when indicated, and sustained lifestyle modification. Recent therapeutic advances, particularly sodium glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, have transformed diabetes management by providing substantial cardiovascular and renal protection in addition to glucose lowering.

A patient-centred, multidisciplinary approach that integrates lifestyle interventions with evidence-based pharmacological therapies remains the cornerstone of diabetes care. Continued research into the molecular mechanisms underlying diabetic cardiovascular disease, together with the development of novel therapeutic strategies and precision medicine approaches, is expected to further improve cardiovascular outcomes and quality of life in this high-risk population. Ultimately, timely diagnosis, individualized treatment, and long-term risk factor modification are critical for preventing cardiovascular complications and reducing diabetes-related mortality worldwide.

REFERENCES

[1] American Diabetes Association, "Standards of care in diabetes—2025," Diabetes Care, vol. 48, Suppl. 1, 2025.
[2] American Heart Association, "Diet and lifestyle recommendations for cardiovascular disease prevention," Circulation, vol. 140, pp. e596–e646, 2019.
[3] Aneja, A., W. H. W. Tang, S. Bansilal, M. J. Garcia, and M. E. Farkouh, "Diabetic cardiomyopathy: Insights into pathogenesis," Circulation Research, vol. 102, pp. 152–162, 2008.
[4] Antithrombotic Trialists' Collaboration, "Aspirin in primary and secondary prevention," The Lancet, vol. 373, pp. 1849–1860, 2009.
[5] Beckman, J. A., M. A. Creager, and P. Libby, "Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management," JAMA, vol. 287, pp. 2570–2581, 2002.
[6] Bhatt, D. L., et al., "Reduction in ischemic events with ticagrelor in diabetes," Journal of the American College of Cardiology, vol. 73, pp. 1490–1500, 2019.
[7] Boudina, S., and E. D. Abel, "Diabetic cardiomyopathy revisited," Circulation, vol. 115, pp. 3213–3223, 2007.
[8] Brownlee, M., "Biochemistry and molecular cell biology of diabetic complications," Nature, vol. 414, pp. 813–820, 2001.
[9] Bugger, H., and E. D. Abel, "Molecular mechanisms of diabetic cardiomyopathy," Diabetologia, vol. 57, pp. 660–671, 2014.
[10] Cannon, C. P., et al., "Ezetimibe added to statin therapy after acute coronary syndromes," The New England Journal of Medicine, vol. 372, pp. 2387–2397, 2015.
[11] Carr, M. E., "Diabetes mellitus: A hypercoagulable state," Journal of Diabetes and Its Complications, vol. 15, pp. 44–54, 2001.
[12] Ceriello, A., "Hyperglycemia and the worse prognosis of COVID-19 in diabetes: A mechanism involving oxidative stress," Diabetes Care, vol. 43, pp. e65–e66, 2020.
[13] Centers for Disease Control and Prevention, National Diabetes Statistics Report 2020. Atlanta, GA, USA: CDC, 2020.
[14] Cholesterol Treatment Trialists' Collaboration, "Efficacy of statins in diabetes," The Lancet, vol. 376, pp. 1670–1681, 2010.
[15] Collet, J. P., et al., "2023 ESC guidelines for the management of acute coronary syndromes," European Heart Journal, vol. 44, pp. 3720–3826, 2023.
[16] DeFronzo, R. A., and E. Ferrannini, "Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerosis," Diabetes Care, vol. 14, pp. 173–194, 1991.

[17] Forbes, J. M., and M. E. Cooper, "Mechanisms of diabetic complications," Physiological Reviews, vol. 93, pp. 137–188, 2013.
[18] Giacco, F., and M. Brownlee, "Oxidative stress and diabetic complications," Circulation Research, vol. 107, pp. 1058–1070, 2010.
[19] Goldberg, I. J., "Diabetic dyslipidemia: Causes and consequences," The Journal of Clinical Endocrinology & Metabolism, vol. 86, pp. 965–971, 2001.
[20] Haw, J. S., et al., "Effects of lifestyle interventions in diabetes prevention," The Lancet, vol. 389, pp. 1119–1128, 2017.
[21] International Diabetes Federation, IDF Diabetes Atlas, 10th ed. Brussels, Belgium: International Diabetes Federation, 2021.
[22] Inzucchi, S. E., et al., "Management of hyperglycemia in type 2 diabetes: 2024 update," Diabetes Care, vol. 47, pp. 275–286, 2024.
[23] Jia, G., M. A. Hill, and J. R. Sowers, "Diabetic cardiomyopathy: An update of mechanisms contributing to this clinical entity," Circulation Research, vol. 122, pp. 624–638, 2018.
[24] Knowler, W. C., et al., "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin," The New England Journal of Medicine, vol. 346, pp. 393–403, 2002.
[25] Look AHEAD Research Group, "Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes," The New England Journal of Medicine, vol. 369, pp. 145–154, 2013.
[26] Low Wang, C. C., C. N. Hess, W. R. Hiatt, and A. B. Goldfine, "Clinical update: Cardiovascular disease in diabetes mellitus," Circulation, vol. 133, pp. 2459–2502, 2016.
[27] Marso, S. P., et al., "Liraglutide and cardiovascular outcomes in type 2 diabetes," The New England Journal of Medicine, vol. 375, pp. 311–322, 2016.
[28] McMurray, J. J. V., H. C. Gerstein, R. R. Holman, and M. A. Pfeffer, "Heart failure: A cardiovascular outcome in diabetes," Circulation, vol. 130, pp. 1578–1589, 2014.
[29] Neal, B., et al., "Canagliflozin and cardiovascular and renal events in type 2 diabetes," The New England Journal of Medicine, vol. 377, pp. 644–657, 2017.
[30] Paneni, F., J. A. Beckman, M. A. Creager, and F. Cosentino, "Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy," European Heart Journal, vol. 34, pp. 2436–2443, 2013.
[31] Pfeffer, M. A., et al., "Lixisenatide in patients with type 2 diabetes and acute coronary syndrome," The New England Journal of Medicine, vol. 373, pp. 2247–2257, 2015.
[32] Piepoli, M. F., et al., "2016 European guidelines on cardiovascular disease prevention in clinical practice," European Heart Journal, vol. 37, pp. 2315–2381, 2016.
[33] Poornima, I. G., P. Parikh, and R. P. Shannon, "Diabetic cardiomyopathy: The search for a unifying hypothesis," Circulation Research, vol. 98, pp. 596–605, 2006.
[34] Rask-Madsen, C., and G. L. King, "Vascular complications of diabetes: Mechanisms of injury and protective factors," Cell Metabolism, vol. 17, pp. 20–33, 2013.
[35] Rubler, S., J. Dlugash, Y. Z. Yuceoglu, T. Kumral, A. W. Branwood, and A. Grishman, "New type of cardiomyopathy associated with diabetic glomerulosclerosis," The American Journal of Cardiology, vol. 30, pp. 595–602, 1972.
[36] Sabatine, M. S., et al., "Evolocumab and clinical outcomes in patients with cardiovascular disease," The New England Journal of Medicine, vol. 376, pp. 1713–1722, 2017.
[37] Singh, V. P., A. Bali, N. Singh, and A. S. Jaggi, "Advanced glycation end products and diabetic complications," The Korean Journal of Physiology & Pharmacology, vol. 18, pp. 1–14, 2014.
[38] Stratton, I. M., et al., "Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes," BMJ, vol. 321, pp. 405–412, 2000.
[39] Tabit, C. E., W. B. Chung, N. M. Hamburg, and J. A. Vita, "Endothelial dysfunction in diabetes mellitus: Molecular mechanisms and clinical implications," Reviews in Endocrine and Metabolic Disorders, vol. 11, pp. 61–74, 2010.
[40] UK Prospective Diabetes Study (UKPDS) Group, "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications

in patients with type 2 diabetes," The Lancet, vol. 352, pp. 837–853, 1998.
[41] Wiviott, S. D., et al., "Dapagliflozin and cardiovascular outcomes in type 2 diabetes," The New England Journal of Medicine, vol. 380, pp. 347–357, 2019.
[42] Yusuf, S., et al., "Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study," The Lancet, vol. 364, pp. 937–952, 2004.
[43] Zinman, B., et al., "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes," The New England Journal of Medicine, vol. 373, pp. 2117–2128, 2015.